Introduction
Universities and certain colleges in the United States (US) spend billions of dollars on research and development (R&D) each
Continue Reading Three (3) Initial Considerations for Entrepreneurial Faculty, Researchers, Post-Docs, and Graduate Students
Google’s parent company Alphabet announced the launch of a new company this week dedicated to applying deep learning methods to
Continue Reading Alphabet Dives Further Into AI-Driven Drug Discovery
Vertex Pharmaceuticals and Mammoth Biosciences, a Brisbane, California-based genetic research company, announced a new collaboration for the development of in
Continue Reading Vertex and Mammoth Biosciences Ink $700M Deal for Ultra-Small CRISPR Systems
On October 6, 2021, Voyager Therapeutics and Pfizer entered into a license option agreement, which allows Pfizer to exercise options
Continue Reading Pfizer and Voyager Agree to Develop Neurologic and Cardiovascular Gene Therapies Valued at up to $630 Million
On September 13, 2021, Regenxbio, a Maryland biotech company, and AbbVie announced that they have entered an agreement to develop
Continue Reading Abbvie and Regenexbio Agree to Develop and Commercialize Eye Disease Gene Therapy
Following the successful development (and financial success) of its mRNA vaccine, biotech company Moderna is now looking to expand into
Continue Reading Moderna’s Next Steps: Spikevax Today, Gene Editing Tomorrow
Caribou Biosciences, Inc., a Berkeley, California-based CRISPR genome-editing biopharmaceutical company, raised $304M in an initial public offering, one of the
Continue Reading Caribou Biosciences Raises $304M in Potentially the Largest Gene Editing IPO
On July 15, 2021, American Gene Technologies (AGT), a Maryland biotech company, announced that the safety data in its Phase
Continue Reading American Gene Technologies Celebrates Milestone in HIV Cure Development
mRNA pioneer BioNTech announced recently that it is developing an mRNA-based vaccine to attempt to eradicate malaria. Its efforts are
On July 13, 2021, Prime Medicine, a Massachusetts biotech company developing next generation gene editing technology, emerged from stealth mode
Continue Reading Prime Medicine Emerges with $315 Million to Develop Next Generation Gene Editing Platform